By Fineline Cube 
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a long-acting C5 complement inhibitor, in the China market. The drug has received approval for use in combination with conventional therapy for adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and for treating adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
Drug Mechanism and Approval Timeline
Ravulizumab is a long-acting C5 complement inhibitor that targets and inhibits the activation of terminal complement C5 in the immune system, providing immediate, complete, and continuous inhibition of complement activation. In China, the drug gained approval for gMG in April 2025 and for NMOSD in August 2025.-Fineline Info & Tech